$76.2M
1 filing since 2023 · latest Equity filed
Quanta Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule allosteric inhibitors of RAS-driven cancers. It targets KRAS mutations beyond G12C — notably G12D and G12V — which together account for a large share of RAS-mutant tumors. Its lead candidate QTX3034 is in Phase 1 dose expansion in pancreatic, colorectal and endometrial cancers, both as monotherapy and in combination with cetuximab and chemotherapy. The company operates from South San Francisco, CA with an additional site in Radnor, PA.
What sets it apart
A proprietary Second Harmonic Generation platform that measures subtle protein conformational changes at high throughput, enabling allosteric drug discovery against RAS signaling complexes previously considered undruggable.
An oral, G12D-preferring multi-KRAS allosteric inhibitor in Phase 1 dose expansion, studied as monotherapy and in combination with cetuximab and chemotherapy in pancreatic, colorectal and endometrial cancers.
